ALPHAMAB ONCOLO.DL-000002 (3NK) — Defensive Interval Ratio
ALPHAMAB ONCOLO.DL-000002 (3NK) has a Defensive Interval Ratio of 1499 days as of December 2025. Defensive assets of €1.15 Billion (cash €-, short-term investments €1.09 Billion, receivables €61.95 Million) cover 1499 days of daily cash needs of €769.44K/day. See how liquid is ALPHAMAB ONCOLO.DL-000002's working capital to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
ALPHAMAB ONCOLO.DL-000002 Defensive Interval Ratio (2021–2025)
This chart shows how ALPHAMAB ONCOLO.DL-000002's Defensive Interval Ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 1499 days, meaning defensive assets of €1.15 Billion can fund 1499 days of operations without new revenue. See ALPHAMAB ONCOLO.DL-000002 balance sheet quality to measure how much of total assets are equity-financed.
Annual Defensive Interval Ratio for ALPHAMAB ONCOLO.DL-000002 (2021–2025)
The table below presents the year-by-year Defensive Interval Ratio for ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see 3NK company net worth.
| Year | DIR (days) | Defensive Assets (EUR) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 1499 days | €1.15 Billion | €769.44K/day | €- | €1.09 Billion | ▲ +815 days |
| 2024 | 684 days | €475.86 Million | €696.01K/day | €- | €459.35 Million | ▲ +235 days |
| 2023 | 449 days | €328.38 Million | €731.06K/day | €- | €321.25 Million | ▲ +168 days |
| 2022 | 281 days | €296.68 Million | €1.05 Million/day | €- | €281.19 Million | ▼ -400 days |
| 2021 | 681 days | €1.19 Billion | €1.75 Million/day | €- | €1.18 Billion | — |